Ecnoglutide Tracker App
Track Your Ecnoglutide Protocol
Ecnoglutide is a glp-1/gcg dual (sciwind) used in Phase 2. Shotlee is the free app to track your complete Ecnoglutide protocol — doses, side effects, weight, and labs.
What Is Ecnoglutide?
Ecnoglutide is a glp-1/gcg dual (sciwind) used in Phase 2. Shotlee is the free app to track your complete Ecnoglutide protocol — doses, side effects, weight, and labs.
Shotlee tracks every aspect of your Ecnoglutide protocol: injection dates, doses, sites, side effects, weight changes, and lab results. Whether you are starting or optimizing, clean data makes better decisions.
What to Track in Shotlee
Build a complete Ecnoglutide protocol record from day one.
How to Track Your Ecnoglutide Protocol
Ecnoglutide Key Facts
Protocol FAQs
Log each injection in Shotlee with the dose, date, injection site, and any side effects. Shotlee keeps a complete timeline of your Ecnoglutide protocol.
Yes. Shotlee supports tracking multiple medications and peptides simultaneously, including combination protocols.
Record every dose, injection site, timing, any side effects, and weekly weight/measurements. This data helps you and your prescriber optimize your protocol.
Yes. Shotlee is completely free for dose logging, side effect tracking, and protocol management. No hidden fees.
Open the Shotlee app, navigate to the dose logging screen, select Ecnoglutide as your medication, and enter the dose amount, injection site, and time. Shotlee stores all entries with timestamps and lets you view your complete dose history, adherence rate, and missed dose alerts. The app is free to download and use.
The most important side effects to track include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), injection site reactions, appetite changes, energy levels, and any unusual symptoms. Log these daily in Shotlee so you can share accurate trend data with your healthcare provider at your next visit.
Most patients begin noticing appetite changes within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight, depending on the dose titration schedule and individual metabolic response. Track your weekly weight in Shotlee to visualize your personal response curve over time.
Track Your Ecnoglutide Protocol in Shotlee
Free dose logs, side effect tracking, weight trends, and lab results — all in one app.
📚References & sources
Latest on Ecnoglutide
Pfizer's Xianweiying GLP-1 Weight Loss Drug Pre-Order in China
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
5 min read
Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval
Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.
5 min read
Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
6 min read